Set for a major rebound on major new catalysts

Bullish pennant formed just prior to FDA putting a partial hold on Inovio's Covid-19 vaccine P2/P3 trials.
Inovio is expected to resolve the FDA's questions within the next 30 days and begin trials with "EXTENSIVE external funding" according to CEO - Dr. Joseph Kim